RAPP (Rapport Therapeutics) Total Stockholders Equity : $285.84 Mil (As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Rapport Therapeutics Total Stockholders Equity?

Rapport Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2025 was $285.84 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Rapport Therapeutics's Book Value per Share for the quarter that ended in Mar. 2025 was $7.83. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Rapport Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2025 was 0.03.

Rapport Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Rapport Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapport Therapeutics Total Stockholders Equity Chart

Rapport Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

Total Stockholders Equity

-10.06

-25.63

305.43

Rapport Therapeutics Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Stockholders Equity	Get a 7-Day Free Trial					-39.63	336.89	323.11	305.43	285.84

Rapport Therapeutics (NAS:RAPP) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Rapport Therapeutics's Book Value per Share for the quarter that ended in Mar. 2025 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(285.836	-	0)	/	36.497
	=	7.83

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Rapport Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2025 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.008	+	6.834)	/	285.836
	=	0.03

Rapport Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Rapport Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Rapport Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rapport Therapeutics Inc (NAS:RAPP) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

1325 Boylston Street, Suite 401, Boston, MA, USA, 02215

Website

https://www.rapportrx.com

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.